US8299223B2ActiveUtilityPatentIndex 59
Pseudoglycolipid and use thereof
Est. expiryFeb 22, 2027(~0.6 yrs left)· nominal 20-yr term from priority
A61P 43/00C07C 323/41C07C 233/36A61P 37/04C07C 233/18A61P 35/00C07C 2601/14C07C 235/08
59
PatentIndex Score
4
Cited by
10
References
6
Claims
Abstract
The invention provides a pseudoglycolipid effective for cancer treatment and the like and a novel synthesis intermediate therefor, as well as a medicament containing the pseudoglycolipid and the like. The inventive compound is represented by the formula (1), or a salt thereof, wherein each symbol is as defined in the specification.
Claims
exact text as granted — not AI-modified1. A compound represented by the following formula (1)
wherein R 1 is a 5a-carba-α-D-galactopyranosyl group, R 2 and R 3 are each independently a substituted or unsubstituted hydrocarbon group having a carbon number of 1 to 28, X is an oxygen atom, and Y is —CH(OH)—, or a salt thereof.
2. The compound of claim 1 , wherein R 2 is a substituted or unsubstituted alkyl group having a carbon number of 1 to 28, or a salt thereof.
3. The compound of claim 1 , wherein R 3 is a substituted or unsubstituted alkyl group having a carbon number of 1 to 28, or a salt thereof.
4. A commercial package comprising a composition comprising a compound represented by the following formula (1)
wherein R 1 is a 5a-carba-α-D-galactopyranosyl group, R 2 and R 3 are each independently a substituted or unsubstituted hydrocarbon group having a carbon number of 1 to 28, X is an oxygen atom, and Y is —CH(OH)—, or a salt thereof, and a written matter describing a method of administration of the composition.
5. The commercial package of claim 4 , wherein R 2 is a substituted or unsubstituted alkyl group having a carbon number of 1 to 28, and R 3 is a substituted or unsubstituted alkyl group having a carbon number of 1 to 28, or a salt thereof.
6. A composition comprising the compound of claim 1 and a pharmacologically acceptable carrier therefor.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.